Targets › CPT1A
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Feb 2027.
Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion. Also possesses a lysine succinyltransferase activity that can regulate enzymatic activity of substrate proteins such as ENO1 and metabolism independent of its classical carnitine…. (UniProt, P50416)
Open in Phaseline: the race on CPT1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sara Refaat Azab Metry | Trimetazidine Dihydrochloride Tablets Mitochondrial fatty acid oxidation inhibitor | CPT1A | Phase 1 | Diabetic Peripheral Neuropathic Pain (DPN) | Feb 2027 |
Diabetic Peripheral Neuropathic Pain (DPN) (1)
small molecule (1)
Sara Refaat Azab Metry (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.